[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-adenocarcinoma":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,48,74,102,129,154,194,217,238,262,286,312,335,363,390,427,453,483,509,536,560,589,614,632,665],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644960","phase-1-inhaled-cromolyn-sodium-in-patients-with-locally-advanced-lung-cancer-100644960",false,"NCT07675876","Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer","An Open-Label Pilot Study Evaluating the Safety, Feasibility, and Preliminary Clinical Activity of Inhaled Cromolyn Sodium in Participants With Locally Advanced Lung Cancer","CS","Inclusion Criteria:\n\nPatients with local advanced stage 3 lung cancer or lung adenocarcinoma will be eligible for the study only if they meet the following criteria:\n\n* Provide written informed consent prior to screening.\n* Male or female patients, age ≥ 18 years\n* Histological- or cytological-confirmed diagnosis of Lung cancer\n* Previous tumor scan location in lung\n\nExclusion Criteria:\n\n* Treatment with another investigational drug, biological agent, or device within 4 weeks (6 weeks for biological agents) before screening or 5 half-lives of study agent, whichever is longer.\n* Patients with known pericardial effusion\n* Patients with active infection or serious concomitant systemic disorder (for example, heart failure) incompatible with the study (at the discretion of the Investigator)\n* Planned concomitant participation in another clinical trial of an experimental agent, vaccine, or device.\n* Patients with any other medical condition that in the opinion of the Investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study.\n* Known allergy or history of serious adverse event with Cromolyn Sodium","ALL","18 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Brief Summary\n\nThis prospective, open-label pilot study is designed to evaluate the safety, tolerability, feasibility, and preliminary clinical activity of inhaled cromolyn sodium administered by dry powder inhalation in participants with locally advanced lung cancer.\n\nCromolyn sodium is an FDA-approved mast cell stabilizer with an established safety profile in respiratory disease. Increasing evidence suggests that inflammatory signaling, mast cell activation, and stromal remodeling contribute to tumor progression, immune dysregulation, and resistance to therapy within the lung tumor microenvironment. Modulation of these pathways may represent a novel therapeutic strategy in lung cancer.\n\nApproximately 5 to 10 participants with locally advanced lung cancer will receive inhaled cromolyn sodium according to the study protocol. Participants will undergo clinical assessments, safety monitoring, laboratory evaluations, and radiographic imaging in accordance with protocol-defined procedures and standard oncologic care.\n\nThe primary objective of this pilot study is to evaluate the safety, tolerability, and feasibility of inhaled Cromolyn sodium administration in this patient population. Secondary objectives include exploratory assessment of radiographic response, clinical outcomes, biomarker trends, and potential signals of biological activity. Data generated from this study are intended to support the development of future clinical investigations evaluating the role of mast cell stabilization and tumor microenvironment modulation in lung cancer.",[28,29],"Locally Advanced Non-Small Cell Lung Cancer","Lung Adenocarcinoma",[31,32,29,33,34],"local advanced lung cancer","Stage 3 lung cancer","Cromolyn Sodium","Dry Powder Inhaler(DPI)","NOT_YET_RECRUITING","2026-06-29",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":22},"2026-08",{"date":43,"type":22},"2027-08",{"name":45,"class":46},"Carcinex Inc","INDUSTRY",2,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100643205","ex-vivo-drug-response-profiling-and-outcome-prediction-in-lung-adenocarcinoma-100643205","NCT07636252","Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma","Inclusion Criteria:\n\n* Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing.\n* Patient's written informed consent present.\n* Ability to understand the nature of the trial and the trial related procedures and to comply with them.\n\nExclusion Criteria:\n\n* negative cytology for malignancy in the last 6 months",{"count":55,"type":22},400,"OBSERVATIONAL","This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.",[29,59],"Malignant Pleural Effusions (Mpe)",[61],"Drug sensitivity testing, malignant pleural effusion, lung cancer","RECRUITING","2026-06-18",{"date":65,"type":39},"2026-06-23",{"date":67,"type":39},"2023-06-14",{"date":69,"type":22},"2030-01-01",{"name":71,"class":72},"Sheba Medical Center","OTHER_GOV",1,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":73},"100301098","beating-lung-cancer-in-ohio-protocol-in-improving-survival-in-patients-with-stage-iv-non-small-cell-lung-cancer-100301098","NCT03199651","Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer","Beating Lung Cancer in Ohio (BLCIO) Protocol","BLCIO","Inclusion Criteria:\n\n* AIM 1-3\n* Pathologically confirmed stage IV NSCLC (with any Eastern Cooperative Oncology Group \\[ECOG\\] performance status, and any NSCLC - adenocarcinoma, squamous cell, etc.) with available imaging OR patients who do not yet have their staging completed, but in the judgment of the physician are likely to be stage IV;\n\n  * Patients may be enrolled if the recruiter cannot reach the patient by the first office visit, preferably prior to starting therapy and no later than one month after starting therapy; (NCCN guidelines allow for a switch to targeted therapy from chemotherapy if testing comes back positive after starting chemotherapy)\n* English speaking; and\n* Willing to provide access to medical records, insurance and billing data, biospecimens and respond to questionnaires, typically by phone, but possibly to include online or in-person surveys\n* AIM 3 ONLY\n* Patients must be current smokers who smoke at least one cigarette most days per week, or recent quitters who smoked at least one cigarette most days per week (\\\u003C 3 months); and\n* Household members must be current smokers, defined as smoking at least one cigarette most days per week\n* Hearing and vision impairments that would prevent ability to complete consent, interviews, or sample collection\n\nExclusion Criteria:\n\n* Being treated with definitive chemoradiotherapy or surgery\n* Receiving treatment for advanced lung cancer for over one month before enrollment; OR",{"count":83,"type":22},3584,[85],"NA","This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorable toxicity profiles than conventional chemotherapy and impact quality of life.",[88,89,29,90,91],"Cigarette Smoker","Current Smoker","Squamous Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer","2026-06-15",{"date":94,"type":39},"2026-06-17",{"date":96,"type":39},"2017-07-17",{"date":98,"type":22},"2028-12-31",{"name":100,"class":101},"Ohio State University Comprehensive Cancer Center","OTHER",{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":128},"100454537","phase-2-testing-the-addition-of-an-anti-cancer-drug-trc102-to-the-usual-chemotherapy-treatment-pemetrexed-cisplatin-or-carboplatin-during-radiation-therapy-for-stage-iii-non-squamous-non-small-cell-lung-cancer-100454537","NCT05198830","Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer","A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed adenocarcinoma or large cell carcinoma of the lung with confirmation by immunohistochemistry (histologic tissue diagnosis is preferred, but cytology is acceptable).\n* Patients must have newly staged IIIA, IIIB or IIIC disease according to the 8th tumor, node, metastasis (TNM) staging classification and to be considered appropriate candidates for aggressive chemoradiotherapy.\n* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \\>= 20 mm (\\>= 2 cm) by chest x-ray or as \\>= 10 mm (\\>= 1 cm) with CT scan, MRI, or calipers by clinical exam.\n* Patients must have diagnosed NSCLC, with no prior overlapping radiation therapy delivered for locally advanced NSCLC. Prior stereotactic radiation therapy for stage I lung cancer without overlapping is allowed. Prior systemic antineoplastic therapy is allowed, as deemed appropriate by the treating physician. Prior surgery is allowed. History of previous stage I NSCLC with new mediastinal nodal recurrence (new stage III are eligible).\n* Age \\>= 18 years. Because no dosing or adverse event data are currently available on the use of TRC102 in combination with pemetrexed, cisplatin, and durvalumab in patients \\\u003C 18 years of age, children are excluded from this study.\n* Body weight \\> 30 kg with acceptable nutritional status based on evaluation by treating physician.\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 1 (Karnofsky \\>= 70%).\n* Leukocytes \\>= 3,000\u002FmcL.\n* Hemoglobin \\>= 9.0 g\u002FdL.\n* Absolute neutrophil count \\>= 1,500\u002FmcL.\n* Platelets \\>= 150,000\u002FmcL.\n* Serum bilirubin within normal institutional limits (0 - 1.2 mg\u002F dl). (This will not apply to patients with confirmed Gilbert's syndrome \\[persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology\\], who will be allowed only in consultation with their physician.).\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\]) =\\\u003C 2.5 x institutional upper limit of normal (=\\\u003C 39 U\u002FL).\n* Alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 2.5 x institutional upper limit of normal (=\\\u003C 52 U\u002FL).\n* Creatinine =\\\u003C 1.3 mg\u002FdL.\n* Measured creatinine clearance \\>= 60 mL\u002Fmin OR glomerular filtration rate (GFR) \\>= 50 mL\u002Fmin\u002F1.73 m\\^2.\n* Acceptable pulmonary function as assessed by treating physician.\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women \\\u003C 60 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women \\>= 60 years of age will be considered post-menopausal.\n* Life expectancy \\>= 12 months.\n* Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\n\n  * They must be stable on their anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on the same regimen; the most recent undetectable viral load must be within the past 12 weeks.\n  * They must have a CD4 count of greater than 250 cells\u002FmcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count \\\u003C 200 cells\u002FmcL over the past 2 years, unless it was deemed related to the cancer and\u002For chemotherapy induced bone marrow suppression.\n\n    * For patients who have received chemotherapy in the past 6 months, a CD4 count \\\u003C 250 cells\u002FmcL during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy.\n  * They must have an undetectable viral load and a CD4 count \\>= 250 cells\u002FmcL within 7 days of enrollment.\n  * They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months.\n  * HIV-infected patients should be monitored every 12 weeks for viral load and CD4 counts.\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class 2B or better.\n* The effects of TRC102 on the developing human fetus are unknown. For this reason and because biochemical inhibitors of the BER pathway agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after completion of durvalumab monotherapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of durvalumab administration, if having sex with women of childbearing potential.\n* Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity who have a legally-authorized representative (LAR) and\u002For family member available will also be eligible.\n* Patients with prior stage I\u002FII non-small cell lung cancer treated with surgery are eligible. Patients with prior stage I NSCLC treated with stereotactic body radiotherapy (SBRT) without overlapping radiation fields would also be eligible. Patients with prior chemotherapy are eligible, at physician's discretion.\n\nExclusion Criteria:\n\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1) with the exception of alopecia.\n* Patients who are receiving any other investigational agents.\n* Patients with treated brain metastases are not eligible as the study is for stage III disease only.\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are not eligible as the study includes only stage III disease.\n* Patients with EGFR or ALK mutations are ineligible.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or other agents used in study.\n* Patients with uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent.\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because TRC102 is a biochemical inhibitor of the BER pathway and durvalumab is an anti-PDL1 antibody, agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with TRC102 or durvalumab, breastfeeding should be discontinued if the mother is treated with TRC102 or durvalumab. These potential risks may also apply to other agents used in this study.\n\n  * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after durvalumab monotherapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of durvalumab.\n* Patients with active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.\\]). The following are exceptions to this criterion:\n\n  * Patients with vitiligo or alopecia.\n  * Patients with hypothyroidism (e.g. following Hashimoto thyroiditis) stable on hormone replacement.\n  * Any chronic skin condition that does not require systemic therapy.\n  * Patients without active disease in the last 5 years may be included but only after consultation with the study physician.\n  * Patients with celiac disease controlled by diet alone.\n* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis \\[TB\\] testing in line with local practice), hepatitis B (known positive HBV surface antigen \\[HBsAg\\] result), or hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).\n* History of allogenic organ transplantation.\n* History of another primary malignancy except for:\n\n  * Malignancy treated with curative intent and with no active disease before the first dose of investigational product (IP) and of low potential risk for recurrence.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated any carcinoma in situ without evidence of disease.\n  * Prostate cancer with stable disease with active or prior treatment that will not interfere with current lung cancer treatment will be eligible.",{"count":110,"type":22},42,[112],"PHASE2","This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agents. It blocks the ability of a cell to repair damage to its deoxyribonucleic acid (DNA) and may kill tumor cells. It may also help some anticancer drugs work better. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy sources to kill tumor cells and shrink tumors. Giving TRC102 in combination with usual care treatment may be more effective than usual care treatment alone in stabilizing and lengthening survival time in patients with stage III non-squamous NSCLC.",[29,115,116,117],"Lung Large Cell Carcinoma","Lung Non-Squamous Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","2026-06-10",{"date":120,"type":39},"2026-06-11",{"date":122,"type":39},"2022-12-15",{"date":124,"type":22},"2027-06-30",{"name":126,"class":127},"National Cancer Institute (NCI)","NIH",34,{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":73},"100643034","vortioxetine-for-cognitive-function-in-alk-positive-nsclc-treated-with-lorlatinib-100643034","NCT07633626","Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib","Potential Effect of Vortioxetine on Cognitive Functioning of Patients With ALK-positive Non-Small Cell Lung Cancer Treated With Lorlatinib","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of ALK\u002FROS1-positive non-small cell lung cancer (NSCLC), stage IIIB\u002FIV.\n* Currently receiving lorlatinib as part of the standard therapeutic regimen.\n* Documented neurocognitive adverse events (NAEs) attributable to lorlatinib.\n* Age \\>= 18 years.\n* ECOG performance status 0-2.\n* Ability to understand and sign informed consent.\n* Expected survival \\>= 6 months.\n* Planned initiation of vortioxetine as part of standard care.\n* Ability to complete neuropsychological tests and questionnaires in Spanish.\n\nExclusion Criteria:\n\n* Prior diagnosis of major cognitive impairment unrelated to cancer treatment.\n* Current use of another antidepressant that cannot be discontinued.\n* Uncontrolled major psychiatric disorder.\n* History of uncontrolled epilepsy or recent seizures.\n* Severe hepatic or renal impairment.\n* Known hypersensitivity to vortioxetine.\n* Participation in another clinical trial within the past 30 days.\n* Inability to provide informed consent.\n* Life expectancy \\\u003C 3 months.\n* Contraindications to vortioxetine (e.g., concomitant MAOI use).\n* Prior vortioxetine use.\n* Severe psychiatric disorders or significant cognitive impairment unrelated to lorlatinib.",{"count":137,"type":22},24,"This observational study evaluates whether vortioxetine - an antidepressant medication with cognitive-enhancing properties - can reduce the neurological and cognitive side effects associated with lorlatinib treatment in patients with non-small cell lung cancer (NSCLC) harboring ALK or ROS1 gene rearrangements.\n\nLorlatinib is a highly effective third-generation tyrosine kinase inhibitor, but it causes neuropsychological adverse events (NAEs) in approximately 42% of patients, including cognitive impairment, mood changes, and speech disturbances. Vortioxetine has demonstrated cognitive improvement in depressed patients and in preclinical models of androgen deprivation therapy-induced cognitive impairment.\n\nTwenty-four adult patients with ALK\u002FROS1-positive NSCLC receiving lorlatinib as standard care and prescribed vortioxetine (10-20 mg\u002Fday) for NAE management will be enrolled. Comprehensive neuropsychological assessments and quality-of-life questionnaires will be conducted at baseline, week 6, week 12, and month 6 to document changes in cognitive function, depressive symptoms, and quality of life.",[140,141,29,142,143,144],"Advanced ALK\u002FROS1-positive NSCLC","Carcinoma, Non-Small-Cell Lung (NSCLC)","ALK-positive Non-small Cell Lung Cancer (NSCLC)","Cognitive Dysfunction","Depression","2026-06-04",{"date":147,"type":39},"2026-06-08",{"date":149,"type":39},"2026-03-10",{"date":151,"type":22},"2027-11-10",{"name":153,"class":101},"Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo",{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":171,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100500508","phase-1-phase-iiia-study-of-azd5335-as-monotherapy-and-combination-therapy-in-participants-with-solid-tumors-100500508","NCT05797168","Phase I\u002FIIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","A Modular Phase I\u002FIIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors","FONTANA","Core Inclusion Criteria:\n\n* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n* Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic research that supports Genomic Initiative. Participants who do not provide informed consent for Optional Genetic Research may still be enrolled in the study.\n* Participant must be ≥ 18 years at the time of signing the informed consent.\n* Willing to provide adequate archival and\u002For baseline tumor sample as applicable per module-specific criteria.\n* For participants who have previously received targeted therapies such as ADCs, a fresh baseline biopsy will be required unless the most recent archival tissue sample was collected after receipt of such treatment.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and\u002For tolerability to prior therapy. Participants with contraindications or who refuse therapy in accordance with local practice may also be considered provided that it is documented that he\u002Fshe was informed about all therapeutic options.\n* Participants must have measurable disease per RECIST v1.1,\n\n  1. A previously irradiated lesion can be considered a target lesion if the lesion is progressing and well defined.\n  2. For participants who undergo biopsies at screening and\u002For on treatment, it is preferred though not required, that the biopsied lesion, be distinct from any target lesion used in the RECIST v1.1 evaluation.\n* Life expectancy ≥ 12 weeks.\n* Adequate organ and marrow function.\n* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\n  (a) Male participants: (i) Male participants who are sexually active with a female partner of childbearing potential must use a male condom (plus an additional contraceptive method) post-screening for at least 8 months following the last dose of study intervention. It is strongly recommended for the female partner of a male participant to also use a highly effective method of contraception throughout this period. In addition, male participants must refrain from freezing or donating sperm while on study and for 8 months following the last dose of study intervention.\n\n  (b) Female participants : (i) Females of childbearing potential must have a negative serum pregnancy test result within 72 hours prior to receiving the first dose of study intervention and a negative urine or serum pregnancy test prior to starting their next cycle of treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n(ii) (ii) Sex and Contraceptive\u002FBarrier Requirements: Highly effective birth control methods include: Total sexual abstinence is an acceptable method provided it is the usual lifestyle of the participant (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments) \\[(periodic abstinence e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to study intervention, and withdrawal are not acceptable methods of contraception\\], a vasectomized partner, Implanon®, bilateral tubal occlusion, intrauterine device\u002Flevonorgestrel intrauterine system, Depo Provera™ injections, oral contraceptive associated with inhibition of ovulation, and Evra Patch™, Xulane™, or NuvaRing®.\n\nFemale participants of childbearing potential who are sexually active with a non-sterilized male partner must agree to use one highly effective method of birth control (defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly), from enrolment throughout the study and for 8 months following the last dose of study intervention. The male partner of a female participant of childbearing potential must also use a male condom (plus spermicide, if available) throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. In addition, female participants must not donate or retrieve for their own use, ova while on study and for 8 months following the last dose of study intervention.\n\nCore Exclusion Criteria:\n\n* Patients with spinal cord compression or a history of leptomeningeal carcinomatosis.\n* Patients with brain metastases unless, asymptomatic, stable, and not requiring continuous corticosteroids at a dose of \\> 10 mg prednisone\u002Fday or equivalent for at least 4 weeks prior to first dose of study intervention.\n* Treatment with any of the protocol defined medications, without adequate washout periods or time before the first dose of study intervention.\n* Unresolved toxicities of Grade ≥ 2 (National Cancer Institute \\[NCI\\] CTCAE v5.0) from prior therapy (excluding vitiligo, alopecia, and endocrine disorders that are controlled with replacement hormone therapy). Participants with stable ≤ Grade 2 neuropathy are eligible.\n* Active infection, including tuberculosis and infections with hepatitis B virus (HBV; verified by known positive hepatitis B surface antigen \\[HBsAg\\] result), hepatitis C virus (HCV) or known HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4+ count ≥ 350\u002Fmm3, no history of acquired immune deficiency syndrome-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen).\n\nPatients with a past or resolved HBV\u002FHCV infection are eligible if:\n\n1. Negative for HBsAg and positive for anti-hepatitis B virus core protein (HBc) or\n2. Are HBsAg + with chronic HBV infection (lasting 6 months or longer) and meet conditions i-iii below:\n\n(i) HBV DNA viral load \\\u003C100 IU\u002FmL. (ii) Have normal transaminase values, or, if liver metastases are present, abnormal transaminases, with a result of aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) \\\u003C3 x upper limit of normal (ULN), which are not attributable to HBV infection.\n\n(iii) Start or maintain antiviral treatment if clinically indicated as per the Investigator or as per local guideline.\n\nNote for Japan: Japanese patients with positive anti-HBs\u002Fanti-HBc and negative HBsAg will be assessed following local guidelines.\n\n(c) Participants testing positive for HCV antibody are eligible only if the polymerase chain reaction test result is negative for HCV RNA.\n\n* Patient has active ILD\u002Fpneumonitis or has a history of (non-infectious) ILD\u002Fpneumonitis that required oral or IV steroids or supplemental oxygen, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n\n  * Patients with a history of radiation pneumonitis which has clinically and radiologically resolved and not requiring treatment with steroids may be eligible.\n* History of another malignancy except for:\n\n  * Malignancy treated with curative intent and with no known active disease for at least 2 years prior to screening of study intervention and with low potential risk for recurrence.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated carcinoma in situ without evidence of disease.\n  * Localized non-invasive solid organ primary disease under surveillance.\n* Patients with any of the following cardiac criteria:\n\n  * History of arrhythmia (such as multifocal premature ventricular contractions, bigeminy, trigeminy, and ventricular tachycardia), which is symptomatic or requires treatment NCI CTCAE v5.0 Grade 3 except for:\n\n    (i) Rate controlled asymptomatic atrial fibrillation.\n    * NOTE: significant abnormalities in serum electrolytes that can increase the risk of arrhythmic events (ie, sodium, potassium, calcium, and magnesium) should be corrected before starting the study intervention.\n  * Uncontrolled hypertension.\n  * Acute coronary syndrome\u002Facute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention, or coronary artery bypass grafting within 6 months of screening.\n  * History of brain perfusion problems (eg, carotid stenosis) or stroke, or transient ischemic attack in the last 6 months prior to screening.\n  * Symptomatic heart failure (as defined by New York Heart Association class ≥ 2).\n  * Prior or current diagnosis of cardiomyopathy considered clinically relevant per investigator's judgement.\n  * Severe uncorrected valvular heart disease.\n  * Mean resting QTcF \\> 470 msec obtained from triplicate electrocardiograms (ECGs) and averaged, recorded within 5 minutes.\n  * Any factor that, in the opinion of the investigator, increases the proarrhythmic risk of QT prolongation, such as congenital long QT syndrome, family history of long QT syndrome, hypertrophic cardiomyopathy, or unexplained sudden cardiac death under 40 years of age.\n* Uncontrolled and\u002For unresolved intercurrent illness within 12 months prior to screening, including but not limited to serious chronic gastrointestinal conditions associated with diarrhea, or illness (including psychiatric illness) and\u002For social situations, in the opinion of the investigator, that would limit compliance with study requirements and activities, substantially increase risk of incurring AEs or compromise the ability of the participant to give written informed consent.\n* Substance abuse or any other medical conditions that would increase the safety risk to the participant or interfere with participation of the participant or evaluation of the clinical study in the opinion of the Investigator.\n* Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Participants, if enrolled, should not receive live vaccine whilst receiving study intervention and up to 3 months after the last dose of study intervention. Participants can receive Coronavirus (COVID)-19 vaccines, at the discretion of the Investigator, following a benefit\u002Frisk evaluation for the individual participant and in accordance with local rules and regulations and vaccination guidelines. Note: If a COVID-19 vaccine is administered it should be done \\> 72 hours prior to study intervention initiation or after completion of the DLT period.\n* For women only - currently pregnant (confirmed with positive pregnancy test or suspected), lactating, breastfeeding, or intention to become pregnant during the study period.\n* Concurrent enrolment in another clinical study, unless it is an observational (non interventional) clinical study or during the follow-up period of an interventional study. Exception: Diagnostic imaging evaluation studies (e.g. PET) may be allowed subject to case-by-case discussion with the Sponsor.\n* Patients with a known hypersensitivity to study intervention or any of the excipients of the product.\n* Involvement in the planning and\u002For conduct of the study (applies to both AstraZeneca staff and\u002For staff at the study site).\n* Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n* Previous enrolment in the present study. \\*\\*Other module specific criteria may apply","130 Years",{"count":164,"type":22},506,[25,112],"This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors",[168,29,169,170],"Ovarian Cancer","Endometrial Cancer","Lung Squamous Cell Carcinoma",[172,173,174,175,176,177,178,179,180,181,182,183,168,29,169,170],"ADC","PARP inhibitor","AZD5335","Torvutatug Samrotecan","Torvu-sam","AZD5305","Saruparib","Bevacizumab","Carboplatin","AZD9574","Palacaparib","Pembrolizumab","2026-06-02",{"date":186,"type":39},"2026-06-03",{"date":188,"type":39},"2023-06-05",{"date":190,"type":22},"2028-01-06",{"name":192,"class":46},"AstraZeneca",60,{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":202,"targetDuration":204,"studyType":56,"phases":4,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":215,"locationsCount":47},"100638915","clinical-study-to-identify-biomarkers-for-tumor-spread-through-air-spaces-status-100638915","NCT07630246","CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS","UNCOVERING THE GENETIC LANDSCAPE OF LUNG ADENOCARCINOMA: A CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS","PAIR-LUNG","Inclusion Criteria:\n\n* Patients older than 18 years old\n* Active early LUAD diagnosis according to the American Joint Committee on Cancer\n* Signed informed consent or previous consent given for future research\n\nExclusion Criteria:\n\n* History of inflammatory bowel disease and autoimmune diseases\n* History of hepatic disease (including history of alcoholic or viral hepatitis)\n* LUAD patients with other active malignancy(ies)\n* Previous treatment for LUAD\n* Incapability of understanding the study and\u002For providing consent\n* Signed informed consent unavailable",{"count":203,"type":22},140,"1 Year","Lung cancer remains a significant challenge in oncology, with poor prognosis for patients, especially those with advanced-stage disease. The phenomenon of tumor spread through air spaces (STAS) in pulmonary cancer has garnered attention for its association with aggressive tumor behavior and adverse clinical outcomes. Spread through air spaces identification has been highly debatable on scientific community as an important prognostic feature for distant and locoregional recurrence and as a key player in the differential diagnosis and selection of the appropriate treatment. The aim of this study is to unravel the complexities of STAS-positive lung adenocarcinoma (LUAD) diagnosis and treatment options. For that, we intend to (1) isolate primary lung cancer tissues from early-stages lung adenocarcinoma to fabricate organoid in vitro models and (2) evaluate the microRNA (miRNA) profile of tumor and healthy tissue samples. This is a Hybrid (prospective and retrospective) observational clinical study with a nested translational study.",[29],[208],"Pulmonary cancer, Lung, Tumor spread through air spaces","2026-06-01",{"date":211,"type":39},"2026-06-05",{"date":209,"type":22},{"date":214,"type":22},"2029-06-30",{"name":216,"class":101},"Universidade Nova de Lisboa",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":73},"100580924","clinical-application-of-pet-imaging-targeting-msln-in-malignant-tumors-100580924","NCT06843629","Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors","Inclusion Criteria:\n\n* Each subject must meet all enrollment criteria to be eligible to participate in the study:\n\n  1. The subject or his\u002Fher legal representative is able to sign and date the informed consent form;\n  2. A commitment to comply with the research procedures and to cooperate in the implementation of the full research process;\n  3. Adult patients or healthy volunteers (aged 18 or above) of either sex;\n  4. Patients with clinically suspected or confirmed malignant tumors such as pancreatic cancer, ovarian cancer, or lung adenocarcinoma (supporting evidence includes serum-related tumor markers, imaging data such as ultrasound, CT, MRI, etc., and histological pathology examination, etc.) and in good general condition;\n  5. Consistent with the results of specific laboratory tests;\n  6. Females of childbearing potential who have been using contraception for at least one month prior to screening and who are committed to using contraception for the entire study period and until a specified time after the end of the study；\n  7. Other set entry criteria.\n\nExclusion Criteria:\n\n* All subjects who meet any of the exclusion criteria baseline will be excluded from the study:\n\n  1. Those who are unable to complete a PET\u002FMR or PET\u002FCT examination (including inability to lie down, claustrophobia, radiophobia, etc.);\n  2. Having other comorbidities;\n  3. Patients with known hypersensitivity to MSLN antibody fragment developers or synthetic excipients; fasting blood glucose level greater than 11.0 mmol\u002FL prior to 18F-FDG injection；\n  4. Have a history of comorbid drug use;\n  5. Patients considered by the investigator to have poor compliance;\n  6. Patients during pregnancy or lactation;\n  7. Persons with other factors that make participation in this test inappropriate.","65 Years",{"count":225,"type":22},100,"The project aims to perform integrated PET\u002FMR or PET\u002FCT visualization of patients with clinically suspected or confirmed pancreatic cancer, ovarian cancer, lung adenocarcinoma and other malignant tumors with high MSLN expression and healthy volunteers, using targeted MSLN-specific imaging agents (taking \\[68Ga\\]Ga-NOTA-MSLN antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \\[18F\\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.",[168,29,228],"Pancreatic Cancer","2026-05-25",{"date":231,"type":39},"2026-05-28",{"date":233,"type":39},"2024-10-01",{"date":235,"type":22},"2028-06-30",{"name":237,"class":101},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":245,"sex":18,"minAge":246,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":73},"100479859","phase-2-osimertinib-to-suppress-the-progression-of-remaining-ggn-for-egfr-mutation-positive-stage-ib-iiia-lung-adenocarcinoma-100479859","NCT05528458","Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma","A Phase II Study of Osimertinib to Suppress the Progression of Remaining Ground-glass Opacity Nodule (GGN) for Actionable EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma","Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Adult male or female patients, aged from 30 to 75 years\n3. Pathologic proven lung adenocarcinoma with additional persistent GGNs in at least one other lobe: GGN is defined as a ground glass-opacity with well-defined margin, mean density above -500 HU and greater than 7.5 mm in its maximum diameter\n4. The resected lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion.\n5. WHO performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks\n6. Complete surgical resection of the primary NSCLC is mandatory.\n7. Uneventful recovery from curative-intent lung cancer surgery\n\nFor assignment in the control arm, subjects should be classified post-operatively as Stage IA on the basis of pathologic criteria (the 8th edition of TNM staging system for lung cancer).\n\nFor assignment in the treatment arm, subjects should fulfil the following criteria in addition to the above criteria.\n\n* Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic cirteria (the 8th edition of TNM staging system for lung cancer)\n* Female subjects should be using highly effective contraceptive measures, and must have a negative pregnancy test and not be breast-feeding prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\n\n  * Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments\n  * Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution\n  * Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation\n\nFurther information in Appendix E (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods)\n\n\\- Male subjects should be willing to use barrier contraception during the study and for 4 months after last dose of osimertinib\n\nExclusion Criteria:\n\n1. Regression of synchronous GGN after adjuvant chemotherapy prior to osimertinib\n2. Past history of postoperative ALI\u002FARDS or pneumonia during recovery period\n3. Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 week prior) (Appendix C). All patients must try to avoid concomitant use of any medications, herbal supplements and\u002For ingestion of foods with known inducer effects on CYP3A4.\n4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n5. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.\n6. Any of the following cardiac criteria:\n\n   * Mean resting corrected QT interval (QTc) \\> 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value. Whenever QTc, is mentioned in this document, this refers to correction e made by Fridericia formula (QTcF),\n   * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.\n   * Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum\u002Fplasma potassium \\\u003C lower limit of normal (LLN); Serum\u002Fplasma magnesium \\\u003C LLN; Serum\u002Fplasma calcium \\\u003C LLN) , congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes\n7. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n8. Inadequate bone marrow reserve or organ function (as demonstrated by any of the following laboratory values:\n\n   * Absolute neutrophil count \\\u003C1.5 x 109\u002FL;\n   * Platelet count \\\u003C100 x 109\u002FL;\n   * Haemoglobin \\\u003C90 g\u002FL;\n   * Alanine aminotransferase \\>2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n   * Aspartate aminotransferase \\>2.5 times ULN if no demonstrable liver metastases or \\>5 times ULN in the presence of liver metastases;\n   * Total bilirubin \\>1.5 times ULN if no liver metastases or \\>3 times ULN in the presence of documented Gilbert's Syndrome \\[unconjugated hyperbilirubinaemia\\] or liver metastases;\n   * Serum creatinine \\>1.5 times ULN concurrent with creatinine clearance \\\u003C50 mL\u002Fmin \\[measured or calculated by Cockcroft and Gault equation\\]-confirmation of creatinine clearance is only required when creatinine is \\>1.5 times ULN.\n9. Women who are breast-feeding\n10. Males and females of reproductive potential who are not using and effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry.\n11. Involvement in the planning and conduct of the study (applies to AstraZeneca staff or staff at the study site).\n12. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.",true,"30 Years","75 Years",{"count":249,"type":22},59,[112],"This is an open label, phase II study to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage IB-IIIA lung adenocarcinoma.",[29],"2026-04-26",{"date":255,"type":39},"2026-04-28",{"date":257,"type":39},"2022-09-11",{"date":259,"type":22},"2027-12-01",{"name":261,"class":101},"Samsung Medical Center",{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":245,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":269,"targetDuration":271,"studyType":56,"phases":4,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":73},"100453972","shared-decision-making-in-patients-with-lung-cancer-100453972","NCT05191485","Shared Decision Making in Patients With Lung Cancer","Shared Decision Making in Patients With Lung Cancer After Surgery：a Molecular Testing Decision Aid Evidence Based Development Study","Inclusion criteria:\n\nPatients of decision-making need assessment:\n\n1\\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have or have not made a decision on lung cancer molecular testing (whether to perform molecular testing or not).\n\nOther stakeholders of decision-making need assessment:\n\n1\\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process.\n\nPatients of Cognitive debriefing\u002FAlpha tests:\n\n1\\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have made a decision on whether to perform lung cancer molecular testing or not.\n\nother stakeholders of Cognitive debriefing\u002FAlpha tests:\n\n1\\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process.\n\nPatients of field testing \u002FBeta tests:\n\n1\\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have not decided whether to perform lung cancer molecular testing or not.\n\nClinician of field testing \u002FBeta tests:\n\n1\\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; and 4) voluntarily participated in this study.\n\nExclusion criteria:\n\nInability to understand the research content.",{"count":270,"type":22},190,"1 Day","The objective of this study is to develop a Decision Aid for Lung Cancer Molecular Testing (DA\\_LCMT) and to facilitate shared-decision making in patients who were diagnosed with lung adenocarcinoma by intraoperative frozen pathology about whether to conduct the molecular testing.",[274,29],"Surgery",[276,277],"Shared-decision making","Decision aid",{"date":279,"type":39},"2026-04-30",{"date":281,"type":39},"2023-02-22",{"date":283,"type":22},"2027-12",{"name":285,"class":101},"Sichuan Cancer Hospital and Research Institute",{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":18,"minAge":293,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":308,"leadSponsor":310,"locationsCount":73},"100530056","pathogenic-variants-in-genes-associated-with-lung-adenocarcinoma-100530056","NCT06181812","Pathogenic Variants in Genes Associated With Lung Adenocarcinoma","Prevalence of Pathogenic or Likely Pathogenic Germline Variants in Cancer Predisposition Genes Among Patients With Lung Adenocarcinoma","Inclusion Criteria:\n\n* Both sexes\n* ≥ 16 years old, according the institutional protocols for new patients admittances.\n* histologically confirmed lung adenocarcinoma (LUAD)\n* Signed written informed consent form\n* A life expectancy greater than 8 weeks.\n* Histologically confirmed LUAD and one of the following conditions: i) LCFH, defined as having one first-degree relative (FDR) or two or more second-degree relatives with LC, irrespective of the age at diagnosis. ii) Age at diagnosis ≤50 years, or ≤60 with a pack-years index. iii) Presence of ≥1 AGAs (EGFR, ALK, ROS1, KRAS, BRAF, MET exon 14 skipping, or RET).\n\nExclusion Criteria:\n\n* A sample of peripheral blood that is not accessible.\n* Insufficient clinical pathological information in the electronic clinical record.\n\nElimination Criteria:\n\n* Withdrawal\n* Insufficient DNA quality and quantity for genomic sequencing analyses.\n* Lost of follow up","16 Years","85 Years",{"count":296,"type":22},332,"The goal of this observational study is to describe the prevalence of germ line-pathogenic variants in Mexican patients with lung adenocarcinoma.\n\nThe main questions it aims to answer are:\n\n1. What is the prevalence of pathogenic variants in genes associated with lung adenocarcinoma in Mexican patients younger than fifty?\n2. Which clinical-pathological characteristics are associated with germ-line pathogenic variants in patients with lung adenocarcinoma?\n3. How actionable somatic mutations are associated with germ line-pathogenic variants of patients with lung adenocarcinoma?\n\nParticipants will be asked to sign an informed consent; after that, they will be instructed to donate 10 ml of peripheral blood by venipuncture in the morning and before the patient has taken morning medication and the first meal, following a period of 8-12 hr fasting.",[29],[300,301,302,303],"Lung adenocarcinoma","Hereditary Cancer","Germline Pathogenic\u002FLikely pathogenic variants","Somatic driver alterations","2026-04-06",{"date":306,"type":39},"2026-04-08",{"date":122,"type":39},{"date":309,"type":22},"2027-12-15",{"name":311,"class":101},"Oscar Gerardo Arrieta Rodríguez",{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":18,"minAge":319,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":334},"100434450","segmentectomy-versus-lobectomy-for-lung-adenocarcinoma--2cm-100434450","NCT04937283","Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm","Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm With Micropapillary and Solid Subtype Negative by Intraoperative Frozen Sections: A Prospective and Multi-center Randomized Controlled Trial Study","Inclusion Criteria:\n\n* Patient aged 20-79 years old, both male or female;\n* Tumor size \\\u003C= 2cm on preoperative CT scan;\n* Peripheral solitary nodule or the associated lesion is MIA or less invasive lesion;\n* Preoperative CT indicated that the nodules were non-pure glass nodules (consolidation to tumor ratio \\>= 0.25);\n* Intraoperative frozen section confirmed invasive lung adenocarcinoma with micropapillary and solid subtype negative (\\\u003C= 5%);\n* Intraoperative frozen section indicated the resection margins was free of tumor cells;\n* Lung function could withstand both lung segmentectomy and lobectomy (FEV1 \\> 1.5L or FEV1% \\>= 60%);\n* Eastern Cooperative Oncology Group, 0 to 2;\n* Volunteer to participate the trial and sign the informed consent, able to comply with the follow-up plan and other program requirements.\n\nExclusion Criteria:\n\n* Radiological pure ground glass nodules (consolidation to tumor ratio \\\u003C 0.25);\n* The nodule is close to the lung hilus and is unable to perform segmentectomy;\n* Intraoperative frozen section confirmed with micropapillary and solid subtype positive (\\> 5%);\n* Intraoperative frozen section confirmed adenocarcinoma in situ and minimally invasive adenocarcinoma;\n* Preoperative imaging examination or EBUS indicated lymph node positive metastasis;\n* Preoperative imaging examination revealed distant metastasis;\n* Patients with severe damage to heart, liver and kidney function (grade 3 \\~ 4, ALT and\u002For AST over 3 times the normal upper limit, Cr over the normal upper limit);\n* Patients with other malignant tumors;\n* Pregnant, planned pregnancy and lactating female patients (urine HCG\\>2500IU\u002FL is diagnosed as early pregnancy);\n* Prior chemotherapy, radiation therapy or any other therapies were performed; 12 participated in other tumors within three months of relevant clinical subjects;\n* Those who have participated in other tumor-related clinical trials within three months;\n* Those are not suitable for participating in trials according to investigator's assessment.","20 Years","79 Years",{"count":322,"type":22},690,[85],"This study aims to evaluate the non-inferiority in recurrence-free survival and overall survival of segmentectomy compared with lobectomy in patients with lung adenocarcinoma ≤ 2 cm with micropapillary and solid subtype negative by intraoperative frozen sections.",[29],{"date":327,"type":39},"2026-04-13",{"date":329,"type":39},"2019-10-01",{"date":331,"type":22},"2028-12-30",{"name":333,"class":101},"Shanghai Pulmonary Hospital, Shanghai, China",14,{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":344,"briefSummary":346,"conditions":347,"keywords":351,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":362},"100629985","phase-3-bevacizumab-plus-fsrt-versus-hippocampus-avoidant-wbrt-in-lung-adenocarcinoma-with-extensive-brain-metastases-100629985","NCT07481786","Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","Application of Bevacizumab Combined With Fractionated Stereotactic Radiotherapy (FSRT-Bev) Versus Hippocampus-Avoidant Whole-Brain Radiotherapy With Simultaneous Integrated Boost (HA-WBRT-SIB) in Patients With Extensive Brain Metastases From Lung Adenocarcinoma: A Phase III Randomized Controlled Trial Evaluating Intracranial Control Efficacy and Neurocognitive Function","Inclusion Criteria:\n\n* Age ≥18 years\n* Pathologically confirmed non-squamous non-small cell lung cancer (adenocarcinoma)\n* Extensive brain metastases meeting any of the following:\n\n1-2 metastases with at least one ≥3 cm in diameter; or 3-10 metastases with at least one ≥2 cm; or 11-20 metastases\n\n* Stable extracranial disease\n* ECOG performance status 0-2\n* Adequate bone marrow, hepatic, and renal function\n* Written informed consent\n\nExclusion Criteria:\n\n* Contraindications to bevacizumab (uncontrolled hypertension, history of bleeding\u002Fthromboembolism, recent surgery, etc.)\n* Leptomeningeal metastasis\n* Prior brain radiotherapy or surgical resection of brain metastases\n* Significant mass effect requiring urgent neurosurgical intervention\n* Severe cardiovascular, vascular, or gastrointestinal disease within 6 months\n* Proteinuria ≥3+ or 24-hour urine protein \\>1 g\n* Other active malignancies (except curable non-melanoma skin cancer or cervical carcinoma in situ)\n* Inability to comply with neurocognitive testing\n* Pregnancy or breastfeeding",{"count":343,"type":22},220,[345],"PHASE3","This is a phase 3, randomized, controlled clinical trial comparing two brain-directed treatment strategies for adult patients with extensive brain metastases from lung adenocarcinoma. The trial compares fractionated stereotactic radiotherapy combined with bevacizumab (FSRT-Bev) versus hippocampus-avoidant whole-brain radiotherapy with simultaneous integrated boost (HA-WBRT-SIB). The main objectives are to evaluate intracranial tumor control and preservation of neurocognitive function .\n\nPatients will be randomly assigned in a 1:1 ratio to receive either FSRT plus bevacizumab or HA-WBRT-SIB. In the experimental group, FSRT is delivered to visible brain tumors over 5 daily treatments (total 30 Gy, 6 Gy per fraction). Bevacizumab is given intravenously every 3 weeks for 4 cycles. In the control group, patients receive hippocampus-avoidant whole-brain radiation (25 Gy) with a simultaneous dose boost to metastatic lesions (40 Gy total) over 10 daily treatments.",[29,348,349,179,350],"Brain Metastases","Radiotherapy, Intensity-Modulated","Whole-Brain Radiotherapy",[29,348,352,179,353],"fractionated stereotactic radiotherapy (FSRT)","Whole-brain radiotherapy with simultaneous integrated boost (HA-WBRT-SIB)","2026-04-03",{"date":304,"type":39},{"date":357,"type":39},"2026-03-20",{"date":359,"type":22},"2029-09-15",{"name":361,"class":101},"Sun Yat-sen University",3,{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":372,"briefSummary":373,"conditions":374,"keywords":376,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":73},"100629778","low-glucosehigh-fat-intake-dietary-regimen-as-a-tool-for-empowering-diagnostic-accuracy-of-2-18ffdg-petct-in-lepidic-predominant-growth-lung-adenocarcinoma-100629778","NCT07479095","Low-glucose\u002FHigh-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET\u002FCT in Lepidic-predominant Growth Lung Adenocarcinoma","KETO-FDG Lung","Inclusion Criteria:\n\n* Written informed consent.\n* Age 18 years or older.\n* CT evidence of a lung nodule suspicious for LPA or lung biopsy positive for LPA.\n* Target nodule diameter at least 10 mm.\n* ECOG performance status 0 to 2.\n* Willingness and ability to adhere to a controlled ketogenic diet for 7 days.\n* Ability to comply with study procedures and visit schedule.\n\nExclusion Criteria:\n\n* Not suitable for prolonged imaging procedures.\n* Renal failure.\n* Type 1 diabetes mellitus.\n* Pancreatitis.\n* Severe dyslipidemia.\n* Other malignancies that are progressing or required active treatment within the previous 3 years.\n* Serious or unstable medical, psychiatric, or substance use disorders that could interfere with study participation.\n* Pregnancy or breastfeeding.\n* Refusal to participate",{"count":371,"type":22},30,[85],"This study evaluates whether a 7-day ketogenic dietary regimen before 2-\\[18F\\]FDG PET\u002FCT can improve the diagnostic accuracy of imaging in adults with suspected or histologically confirmed lepidic-predominant lung adenocarcinoma (LPA). LPA frequently shows low glucose metabolism and may yield false-negative FDG PET\u002FCT results. Approximately 30 participants will undergo a tailored ketogenic diet for 7 days before PET\u002FCT. Imaging results will be compared with histopathology and additionally assessed against literature-reported diagnostic performance and a matched retrospective institutional cohort.",[375,29],"Lepidic-Predominant Lung Adenocarcinoma",[377,378,379,380,381],"2-[18F]FDG PET\u002FCT","Ketogenic Diet","Lepidic Adenocarcinoma","Lung Nodule","Diagnostic Accuracy","2026-03-18",{"date":357,"type":39},{"date":385,"type":39},"2025-07-03",{"date":387,"type":22},"2027-03-30",{"name":389,"class":101},"Fondazione del Piemonte per l'Oncologia",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":247,"enrollmentInfo":397,"targetDuration":4,"studyType":23,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":362},"100371641","phase-1-gene-modified-immune-cells-after-conditioning-regimen-for-the-treatment-of-stage-iiic-or-iv-melanoma-or-metastatic-solid-tumors-100371641","NCT04119024","Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors","Inclusion Criteria:\n\n* Histologically confirmed malignancy that is considered surgically incurable with either:\n\n  * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis\n  * Stage IV melanoma including patients with known brain metastases\n  * Other metastatic, non-central nervous system (CNS) solid tumor relapsed or refractory after all standard-of-care systemic therapies for which the patient is eligible\n* Confirmed IL13Ralpha2 tumor expression by immunohistochemistry (immunohistochemical assay \\[IHA\\] H-Score \\>= 50 in at least 10% of the total tumor specimen and in at least two high-power fields)\n* Age greater than or equal to 18 years old and less than 75 years old\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* A minimum of one measurable lesion defined as:\n\n  * Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), OR\n  * Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)\n* Absolute neutrophil count (ANC) \\>= 1 x 10\\^9 cells\u002FL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Platelets \\>= 75 x 10\\^9\u002FL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Hemoglobin \\>= 9.5 g\u002FdL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Aspartate and alanine aminotransferases (AST, ALT) =\\\u003C 2.5 x upper limit of normal (ULN) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Total bilirubin =\\\u003C 2 x ULN (except patients with documented Gilbert's syndrome) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Creatinine \\\u003C 2 mg\u002FdL (or a glomerular filtration rate \\> 45) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Patients with melanoma must have progressed following \\>= 1 line of systemic therapy, including immune checkpoint inhibitor and a BRAF inhibitor in combination with MEK inhibitor for patients with BRAF V600-activating mutation and is not considered to have an alternate treatment option with curative intent\n* Must be willing and able to accept at least one leukapheresis procedure (This does not apply for patients receiving a second infusion of IL13R a2 CAR T cells as they will not undergo leukapheresis)\n* Must be willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to purify \\>= 1 x 10\\^7 T cells from leukapheresis product (this does not apply to patients receiving a second infusion of IL13Ra2 CAR T cells as they will not undergo leukapheresis)\n* Previously known hypersensitivity to any of the agents used in this study; known sensitivity to cyclophosphamide or fludarabine\n* Received systemic treatment for cancer, including immunotherapy, within 14 days prior to initiation of conditioning chemotherapy administration within this protocol\n* Clinically active brain metastases. Radiological documentation of absence of active brain metastases at screening is required for all patients. Prior evidence of brain metastasis successfully treated with surgery or radiation therapy will not be exclusion for participation as long as they are deemed under control at the time of study enrollment\n* Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 2 weeks prior to enrollment; not including patients with primary or secondary adrenal insufficiency who require physiologic replacement with steroids, or patients on inhaled or topical steroids at standard doses\n* Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion. If there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and\u002For infectious disease specialist\n* Hepatitis B or C seropositivity with evidence of ongoing liver damage, which would increase the likelihood of hepatic toxicities from the chemotherapy conditioning regimen and supportive treatments. If there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and\u002For infectious disease specialist\n* Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol\n* A Tiffeneau-Pinelli index \\\u003C 70% of the predicted value. Subjects will be excluded if pulmonary function tests indicate they have insufficient pulmonary capability\n* Patients will be excluded if they have a history of clinically significant electrocardiography (ECG) abnormalities, symptoms of cardiac ischemia or arrhythmias and have a left ventricular ejection fraction (LVEF) \\\u003C 45% on a cardiac stress test (stress thallium, stress multigated acquisition scan (MUGA), dobutamine echocardiogram, or other stress test)\n* Patients with ECG results of any conduction delays (PR interval \\> 200 ms, corrected QT (QTC) \\> 480 ms), sinus bradycardia (resting heart rate \\\u003C 50 beats per minute), sinus tachycardia (HR \\> 120 beats per minute) will be evaluated by a cardiologist prior to starting the trial. Patients with any arrhythmias, including atrial fibrillation\u002Fatrial flutter, excessive ectopy (defined as \\> 20 ventricular premature complex \\[PVC\\]s per minute), ventricular tachycardia, 3rd degree heart block will be excluded from the study unless cleared by a cardiologist\n* Pregnancy or breast-feeding. Female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and for 6 months afterwards. All female patients with reproductive potential must have a negative pregnancy test (serum\u002Furine) at screening and again within 14 days from starting the conditioning chemotherapy. The definition of effective contraception will be based on the judgment of the study investigators. Patients who are breastfeeding are not allowed on this study\n* A concomitant active malignancy that would be considered to interfere with the assessment of the primary or secondary endpoints of the study",{"count":398,"type":22},18,[25],"This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patient's own blood, grown in a laboratory, and modified by adding the IL13Ralpha2 CAR gene. The IL13Ralpha2 CAR gene is inserted into T cells with a virus called a lentivirus. The lentivirus allows cells to make the IL13Ralpha2 CAR protein. This CAR has been designed to bind to a protein on the surface of tumor cells called IL13Ralpha2. This study is being done to determine the dose at which the gene-modified immune cells are safe, how long the cells stay in the body, and if the cells are able to attack the cancer.",[402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,29,417],"Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Recurrent Malignant Solid Neoplasm","Refractory Malignant Solid Neoplasm","Uveal Melanoma","Acral Melanoma","Neuroendocrine Tumors","Paraganglioma","Pheochromocytoma","Adrenocortical Carcinoma","Pancreatic Neuroendocrine Tumor","Thyroid Cancer","Breast Cancer","Head and Neck Squamous Cell Carcinoma","2026-03-13",{"date":420,"type":39},"2026-03-17",{"date":422,"type":39},"2025-10-07",{"date":424,"type":22},"2026-10",{"name":426,"class":101},"Anusha Kalbasi",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":435,"conditions":436,"keywords":439,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":73},"100593924","pleural-effusion-biomarkers-in-lung-adenocarcinoma-patients-100593924","NCT07012759","Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients","Novel Pleural Effusion Biomarkers Screening and Evaluation in Lung Adenocarcinoma Patients","Inclusion Criteria:\n\n* Patients requiring thoracentesis for pleural effusion drainage as determined by a physician based on clinical need.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients under the age of 18.\n* Patients with malignancies other than lung adenocarcinoma.",{"count":225,"type":22},"This project aims to assess the expression levels of novel molecular markers identified through screening in clinical samples of malignant pleural effusion, to evaluate the feasibility and clinical utility of these markers as potential diagnostic genes for lung adenocarcinoma.",[437,29,438],"Biomarkers","Pleural Effusion",[440,441,442,443],"Pleural effusion","biomarkers","lung cancer","clinical diagnosis","2026-03-04",{"date":446,"type":39},"2026-03-05",{"date":448,"type":39},"2025-06-10",{"date":450,"type":22},"2026-12-31",{"name":452,"class":101},"Fu Jen Catholic University",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":471,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":73},"100609797","engagement-of-veterans-with-lung-cancer-100609797","NCT07219251","Engagement of Veterans With Lung Cancer","Engagement of Veterans With Lung Cancer (EVLC)","EVLC","Inclusion Criteria:\n\n1. Veteran patients with diagnosis of any stage of lung cancer;\n2. 18 years of age or older;\n3. English- or Spanish-speaking;\n4. can self-administer questionnaires in English or Spanish;\n5. valid telephone number;\n6. receiving oncology care at participating sites;\n7. currently newly diagnosed or receiving or having completed systemic anti-cancer therapy and\u002For radiation therapy within 12 months, defined as oral, injection, or intravenous therapy (chemotherapy, targeted therapy, or immunotherapy)\n\nExclusion Criteria:\n\n1. no capacity to consent;\n2. actively receiving hospice care",{"count":462,"type":22},194,[85],"This research study will help our understanding of whether additional support for Veterans with lung cancer can improve their quality of life.",[466,29,467,468,469,470],"Lung Cancer (NSCLC)","Lung Cancer, Non-Small Cell","Lung Carcinoma","Lung Cancer, Small Cell","Lung Adenocarcinoma With Bronchiolo-alveolar Feature",[472,473],"lung","cancer","2026-03-02",{"date":476,"type":39},"2026-03-03",{"date":478,"type":39},"2026-02-27",{"date":480,"type":22},"2032-12-31",{"name":482,"class":101},"Palo Alto Veterans Institute for Research",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":23,"phases":491,"briefSummary":492,"conditions":493,"keywords":496,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":73},"100625479","partial-tumor-irradiation-and-immunotherapy-for-unresectable-lung-cancer-100625479","NCT07423169","Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer","Rechallenge Using Combined Partial Tumor Irradiation and Immune Checkpoint Inhibitor-based Immunotherapy for Unresectable Lung Adenocarcinoma: a Pilot Study","Inclusion Criteria:\n\n1. Written informed consent\n2. Biopsy proven unresectable lung adenocarcinoma\n3. Ineligibility for surgery and conventional curative (whole tumor) radiotherapy, and relapsed\u002Frefractory to any previous standard of care therapy including ICI\n4. Age ≥ 18 years,\n5. Female patients must either be of non-reproductive potential (i.e. post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) OR women of fertile age must have adequate conception prevention measures and must have a negative serum pregnancy test upon study entry,\n6. Patient is willing and able to comply with the follow up including scheduled visits and examinations,\n7. Adequate immune blood profile (not being immunodepressed): Leucocyte count ≥4000, Neutrophils count ≥1000.\n8. PDL-1 ≥ 1%\n\nExclusion Criteria:\n\n1. Patients with resectable\u002Fcurable lung cancer\n2. Tumors suitable for the standard of care therapies including surgery or conventional curative (whole tumor) radio-chemotherapy\n3. Lung cancer histology other than adenocarcinoma\n4. Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control\n5. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, (1)\n6. Patients with uncontrolled seizures.\n7. Inadequate immune blood profile (being potentially immunodepressed): Leucocyte count \\\u003C4000, Neutrophils count \\\u003C1000.\n8. PDL-1 \\\u003C 1%",{"count":21,"type":22},[85],"The present study will explore a novel treatment strategy for unresectable lung adenocarcinoma combining a unique unconventional radiotherapy technique for high dose partial tumor irradiation (PTI) sparing the peritumoral immune microenvironment (PIM) with an immune checkpoint inhibitor (ICI)-based immunotherapy. The present study will focus on patients with larger, unresectable bulky lung tumors who previously failed standard of care therapy, or are unsuitable for conventional radio-chemotherapy due to tumor size and volume, and do not have any further therapeutic option left. This concept implies that a very high, ablative radiation dose (typically 20-25Gy per fraction) is delivered exclusively to the central bulky-tumor segment sparing at the same time surrounding PIM and therefore preserving its function.\n\nThe present study will explore the potential clinical advantages of the above described innovative treatment concept as a rechallenge treatment: following the disease progression during initiated first-line ICI-therapy, or following discontinuation of ICI-therapy, a same previously used agent (ICI) will be added the PTI to boost its immunologic anti-tumor effects. The treatment response will be measured by comparing the progression-free survival 1 (PFS-1) (ICI-therapy alone) and progression-free survival 2 (PFS-2) (combined rechallange PTI-ICI) rates.\n\nThe primary endpoint will be ∆PFS rate (PFS-2 vs PFS-1) assessed according to the modified iRECIST criteria. Secondary endpoints will include overall survival, toxicity, and exploration and validation of the anti-cancer immunity.\n\nOnce treatment is completed, follow up will be performed on a regular basis (at 6 and 12 weeks, and every 3 months later on) by CT, MRT or PET-CT imaging to allow for endpoints assessment, or at any time in case of suspected disease progression. Patients will also be followed clinically with history and physical examinations, vital signs, and laboratory examinations as indicated.",[29,494,495],"Bulky Tumors","Unresectable Cancer",[497,498,499],"Partial Irradiation","Immunomodulation","Radio-Vaccine","2026-02-18",{"date":502,"type":39},"2026-02-20",{"date":504,"type":39},"2026-02-02",{"date":506,"type":22},"2028-02",{"name":508,"class":101},"Karl Landsteiner University of Health Sciences",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":18,"minAge":516,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":23,"phases":519,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":73},"100611030","early-phase-1-testing-the-safety-of-dapagliflozin-prior-to-surgery-for-the-treatment-of-patients-with-stage-ia-lung-adenocarcinoma-100611030","NCT07235280","Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma","An Open-Label Safety and Tolerability Pilot Study of Dapagliflozin in Stage IA Lung Adenocarcinoma","Inclusion Criteria:\n\n* Must be able to provide written informed consent\n* Male or female ≥ 22 years of age at visit 1\n* Histologically confirmed stage Ia lung adenocarcinoma, with availability of biopsy tissue for Ki-67 determination\n* Planning to undergo surgery for lung adenocarcinoma\n* Willing and able to receive a research CT-guided lung biopsy\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n* Leukocytes ≥ 3.0 K\u002Fmm\\^3\n* Absolute neutrophil count ≥ 1.5 K\u002Fmm\\^3\n* Platelets ≥ 100 K\u002Fmm\\^3\n* Total bilirubin ≤ 2 mg\u002Fdl\n* Aspartate aminotransferase (AST) ≤ 62 IU\u002FL\n* Alanine aminotransferase (ALT) ≤ 70 IU\u002FL\n* Estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fmin\u002F1.73m\\^2\n* Diabetic status: diabetic subjects who are not currently receiving treatment will be included in the study. Diabetic subjects who are under treatment with insulin or oral anti-diabetic drugs will be enrolled under observation by endocrinologists on the team, to adjust the dose of the standard of care diabetic drugs to prevent hypoglycemia\n* Females of child-bearing potential must have a negative pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Females of childbearing potential must agree to avoid pregnancy during the study and omit to abstinence from heterosexual intercourse or agree to use two methods of birth control (one highly effective method and one additional effective method) at least 4 weeks before the start of protocol therapy\n* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. Women of child-bearing age will receive a urine pregnancy test to confirm eligibility\n* Unsuitable candidate for the study, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the study\n* Current or previous treatment with SGLT2 inhibitors\n* History of other malignancies with exception of malignancies for which all treatment was completed at least 2 years before registration with no evidence of disease and locally treated skin squamous or basal cell carcinoma\n* Currently receiving any other investigational agents\n* Currently receiving regularly scheduled systemic steroids in the form of prednisone or dexamethasone (more than 10 mg prednisone daily or equivalent). Topical steroid ointments or creams for occasional skin rash is allowed\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to dapagliflozin\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, ketoacidosis, severe kidney disease (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73m\\^2)\n* Subjects with HIV are eligible unless their cluster of differentiation 4 (CD4+) T-cell counts are \\\u003C 350 cells\u002FµL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective antiretroviral therapy (ART) according to Department of Health and Human Services (DHHS) treatment guidelines is recommended","22 Years",{"count":518,"type":22},48,[520],"EARLY_PHASE1","This early phase I trial tests the safety and side effects of dapagliflozin given prior to surgery in patients with stage IA lung adenocarcinoma. Dapagliflozin is approved by the Food and Drug Administration (FDA) for the treatment of diabetes and heart failure. It is an SGLT2 inhibitor. Stage I lung adenocarcinomas express significantly higher levels of the SGLT2 protein than other stages, and research suggests that SGLT2 inhibition improves lung cancer outcomes in patients with diabetes. In this study, dapagliflozin is being used off-label, which means it is being used for a condition that it was not originally approved for by the FDA. The investigational study drug is a neoadjuvant treatment, meaning the drug is given before surgery to try and help make the surgery more effective.",[29,523,524,525,526],"Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8","Lung Cancer","2026-02-17",{"date":529,"type":39},"2026-02-19",{"date":531,"type":39},"2025-12-02",{"date":533,"type":22},"2029-06-29",{"name":535,"class":101},"Jonsson Comprehensive Cancer Center",{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":247,"enrollmentInfo":544,"targetDuration":4,"studyType":23,"phases":546,"briefSummary":547,"conditions":548,"keywords":549,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":558,"locationsCount":4},"100624932","phase-2-phoenix-ql1706-plus-chemotherapy-and-bevacizumab-in-aga-resistant-pd-l1-50-non-squamous-nsclc-100624932","NCT07416058","PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","A Multicenter Study of Iparomlimab and Tuvonralimab (QL1706) Plus Platinum-Based Doublet Chemotherapy and Bevacizumab in PD-L1 ≥50% Non-Squamous Non-Small Cell Lung Cancer With Actionable Genomic Alterations (AGA) Resistant to Prior Targeted Therapy","PHOENIX","Inclusion Criteria:\n\nThe study will enroll adult patients (aged 18-75 years) with histologically confirmed locally advanced or metastatic NSCLC (AJCC 9th Edition, Stage IIIB-IVB), and harbor confirmed actionable driver mutations for which targeted therapies are available; these mutations are stratified as follows: EGFR (19del, L858R); ALK, ROS1, RET fusions; KRAS G12C; BRAF V600; and HER2 exon 20 insertions. Patients must have disease progression following at least one line of TKI therapy and a 2-week washout period is required for prior TKI therapy or chemotherapy. Prior immunotherapy is not permitted. PD-L1 tumor proportion score (TPS) ≥ 50%, as confirmed by central laboratory testing using the 22C3 or SP263 clone on fresh or archival tumor tissue (collected within 2 years). Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, and presence of at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.\n\nExclusion Criteria:\n\n* Prior treatment with QL1706 or other investigational PD-1\u002FPD-L1\u002FCTLA-4 antibodies, unless allowed by the protocol.\n* Untreated or symptomatic central nervous system (CNS) metastases. Participants with previously treated, stable, and asymptomatic CNS metastases off steroids for at least 2 weeks before first dose may be eligible.\n* History of severe allergic reactions or hypersensitivity to monoclonal antibodies, platinum agents, pemetrexed, bevacizumab, or any excipients of the study drugs.\n* Clinically significant cardiovascular disease, including but not limited to:\n* Uncontrolled hypertension despite optimal medical management\n* New York Heart Association (NYHA) class III or IV heart failure\n* Unstable angina, myocardial infarction, or stroke within 6 months prior to enrollment\n* Significant arrhythmias requiring anti-arrhythmic therapy\n* Active or history of autoimmune disease that has required systemic treatment in the past 2 years (e.g., with disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for conditions such as vitiligo, resolved childhood asthma\u002Fatopy, or hypothyroidism on stable replacement therapy.\n* Active infection requiring systemic therapy, including known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection, unless well controlled according to protocol-defined criteria.\n* Significant hemoptysis (e.g., ≥ 2.5 mL of bright red blood) within 3 months prior to enrollment or any evidence of high-risk bleeding or coagulation disorder that would contraindicate bevacizumab.\n* Major surgery within 4 weeks before first dose of study treatment or anticipated need for major surgery during the study.\n* Pregnant or breastfeeding women.\n* Any other serious medical condition, uncontrolled intercurrent illness, psychiatric illness, or social circumstance that, in the opinion of the investigator, would compromise the participant's safety, interfere with study evaluations, or preclude informed consent.",{"count":545,"type":22},61,[112],"The goal of this Phase II clinical trial (The PHOENIX Study) is to evaluate if the combination of QL1706 (Iparomlimab and Tuvonralimab), bevacizumab, and chemotherapy can treat patients with TKI-refractory, driver-gene positive (e.g., EGFR, ALK, ROS1, RET, KRAS, BRAF, HER2), non-squamous non-small cell lung cancer (NSCLC) who have high PD-L1 expression (TPS ≥50%).\n\nThe main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nDoes the quadruple combination therapy improve the Objective Response Rate (ORR) compared to historical chemotherapy data? What are the secondary efficacy outcomes, including Progression-Free Survival (PFS) and Overall Survival (OS)?\n\nIf there is a comparison group: There is no concurrent control group (this is an open-label, multi-cohort study). Researchers will compare the treatment outcomes of the participants to historical control data (standard platinum-based chemotherapy) to see if the objective response rate (ORR) improves from a historical baseline of 29% to a target of 55%.\n\nParticipants will:\n\nReceive induction therapy every 3 weeks for 4 cycles, consisting of intravenous infusions of QL1706, bevacizumab, pemetrexed, and platinum chemotherapy (cisplatin or carboplatin).\n\nReceive maintenance therapy every 3 weeks with QL1706 and bevacizumab for up to 2 years or until disease progression.\n\nUndergo regular tumor assessments (CT or MRI scans) to monitor disease status according to RECIST v1.1 criteria.\n\nProvide blood samples for safety monitoring and potential biomarker analysis.",[29],[550,551,552],"PD-L1","CTLA-4","QL1706","2026-02-10",{"date":527,"type":39},{"date":556,"type":22},"2026-01-31",{"date":98,"type":22},{"name":559,"class":101},"Guangdong Association of Clinical Trials",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":567,"enrollmentInfo":568,"targetDuration":570,"studyType":56,"phases":4,"briefSummary":571,"conditions":572,"keywords":576,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":4},"100623087","peripheral-blood-etasts-for-predicting-efficacy-of-chemoimmunotherapy-in-nsclc-100623087","NCT07392073","Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC","Prospective Study of Changes in Peripheral Blood Effector Tumor Antigen-Specific T Cells for Predicting Efficacy of Chemoimmunotherapy in Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)\n* Planned to receive PD-1 inhibitor combined with platinum-based chemotherapy (e.g., pembrolizumab + pemetrexed\u002Fcarboplatin)\n* Age 18-80 years\n* ECOG performance status 0-1\n* Expected survival ≥12 weeks\n* Adequate bone marrow function: ANC ≥1.5×10⁹\u002FL, PLT ≥100×10⁹\u002FL\n* Adequate hepatorenal function: Cr ≤1.5×ULN, ALT\u002FAST ≤2.5×ULN\n* At least one measurable lesion per RECIST 1.1 criteria\n* Able to provide informed consent and comply with study procedures including serial blood sampling and imaging follow-up\n\nExclusion Criteria:\n\n* No measurable disease per RECIST 1.1 criteria\n* Tumor emergencies requiring immediate intervention (spinal cord compression, superior vena cava syndrome)\n* Active untreated central nervous system metastases or leptomeningeal disease\n* Prior treatment with immune checkpoint inhibitors within 4 weeks before enrollment\n* Chronic use of immunosuppressive agents (e.g., corticosteroids \\>10 mg\u002Fday prednisone equivalent)\n* Coagulation disorders (INR \\>1.5 or APTT \\>1.5×ULN) or ongoing anticoagulation therapy\n* Poor vascular access precluding serial venipuncture (\\>5 mL per draw)\n* Active hepatitis B (HBV DNA \\>2000 IU\u002FmL), hepatitis C, or HIV infection\n* Uncontrolled bacterial or fungal infection requiring systemic treatment\n* Pregnancy or lactation\n* Severe psychiatric disorder or communication barriers affecting informed consent or follow-up compliance\n\nWithdrawal Criteria:\n\n* Participant voluntary withdrawal with signed withdrawal statement\n* Major protocol violations: failure to receive ≥2 cycles of planned chemoimmunotherapy; missing ≥2 critical timepoint blood samples (baseline, cycle 2)\n* Uncontrollable grade ≥3 immune-related adverse events requiring permanent discontinuation of PD-1 inhibitor\n\nStudy Termination Criteria:\n\n* Disease progression confirmed by imaging per RECIST 1.1 or clinical progression requiring radiotherapy\n* Death or loss to follow-up \\>6 months\n* Unacceptable grade 4 treatment-related toxicity\n* Investigator determination that continued participation poses health risk to patient\n* Study terminated by ethics committee for scientific or administrative reasons","80 Years",{"count":569,"type":22},80,"24 Months","The goal of this observational study is to explore whether changes in peripheral blood effector tumor antigen-specific T cells (ETASTs) can predict treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC) receiving chemoimmunotherapy. The study aims to:\n\n* Evaluate the relationship between ΔETAST levels (baseline to cycle 2) and progression-free survival\n* Compare the predictive performance of ΔETASTs with traditional biomarkers (PD-L1, TMB)\n* Assess whether ΔETASTs can identify patients more likely to benefit from PD-1 inhibitor plus chemotherapy\n\nParticipants will:\n\n* Provide peripheral blood samples at baseline and after cycle 2 of treatment\n* Undergo ETAST quantification using the CTT-NanoDT technology with TATAN nanoparticles\n* Have standard tumor assessments every 2 cycles according to RECIST 1.1 criteria\n* Be followed for progression-free survival and overall survival up to 24 months",[573,29,170,574,91,575],"Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer","Advanced Non-Small Cell Lung Cancer",[577,578,579,437,580],"Tumor Antigen-Specific T Cells","Effector T Cells","Circulating T Cells","PD-1 Inhibitor",{"date":582,"type":39},"2026-02-06",{"date":584,"type":22},"2026-04",{"date":586,"type":22},"2029-06",{"name":588,"class":101},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":23,"phases":599,"briefSummary":600,"conditions":601,"keywords":603,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":73},"100388544","phase-3-cryoablation-in-combination-or-not-with-pembrolizumab-and-pemetrexed-carboplatin-in-1st-line-treatment-for-patients-with-metastatic-lung-adenocarcinoma-100388544","NCT04339218","Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma","Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study","CRYOMUNE","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed non-small lung adenocarcinoma.\n2. Metastatic disease.\n3. Treatment with pembrolizumab in combination with pemetrexed-carboplatin as per market authorization.\n4. At least two target lesions (RECIST1.1), measurable with CT or MRI :\n\n   1. One target lesion that is amenable for accurate repeated measurements,\n   2. One target lesion (15-40 mm) that is amenable for cryoablation treatment including lung, kidney, adrenal, soft tissue and lytic bone lesions. Liver and sclerotic bone lesions are not allowed to be treated by cryoablation.\n5. Age ≥ 18.\n6. Performance status ≤ 2.\n7. Women of childbearing potential must have a negative serum pregnancy test prior to registration.\n8. Recovery to grade ≤ 1 from any adverse event derived from previous treatment (excluding alopecia)\n9. Patients with a social security in compliance with the French law (Loi Jardé).\n10. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.\n11. Voluntarily signed and dated written informed consents prior to any study specific procedure.\n\nExclusion Criteria:\n\n1. Squamous cell tumors and other than adenocarcinoma.\n2. Prior systemic treatment for advanced non-small cell lung cancer (except adjuvant therapy after complete resection).\n3. Current or prior use of immunosuppressive medication including any use of oral glucocorticoids, within 21 days before the first dose of pembrolizumab.\n4. Known contra-indication and\u002For hypersensitivity to PD1\u002FPD-L1 antagonist and\u002For cytotoxic therapy.\n5. Known contra-indication to cryoablation.\n6. Abnormal coagulation contraindicating biopsy.\n7. Prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma or incidentally discovered good prognosis prostate cancer (T stage \\\u003C pT3 and Gleason ≤ 7).\n8. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.\n9. Subjects who participated in an investigational drug or device study within 28 days prior to study entry.\n10. Known infection with HIV, hepatitis B, or hepatitis C.\n11. Females who are pregnant or breast-feeding.\n12. Men or women refusing contraception.\n13. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.\n14. Previous enrolment in the present study.\n15. Individuals deprived of liberty or placed under legal guardianship.",{"count":598,"type":22},214,[345],"This study aims to compare the one-year survival benefit of the association of cryoablation-pembrolizumab-pemetrexed-carboplatin versus pembrolizumab-pemetrexed-carboplatin in metastatic lung adenocarcinoma patients.\n\nThis is a multicenter, prospective, open-labeled, 2-arm comparative randomized (1:1) phase III trial.\n\nPatients will be randomized with a 1:1 ratio into:\n\n* Arm A (experimental arm): cryoablation of one visceral lesion or bone metastasis excluding liver and sclerotic bone metastases combined with pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.\n* Arm B (standard arm): pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.\n\nPembrolizumab and pemetrexed-carboplatin will be prescribed and administered at the dose recommended by market authorization.\n\nCryoablation treatment should be performed within 6 weeks after the first administration of pembrolizumab. No treatment switching permitted.",[29,602],"Cryotherapy Effect",[604],"Lung adenocarcinoma, immunotherapy, cryoablation","2026-01-28",{"date":607,"type":39},"2026-01-30",{"date":609,"type":39},"2020-08-28",{"date":611,"type":22},"2028-08-27",{"name":613,"class":101},"Institut Bergonié",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":622,"conditions":623,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":630,"locationsCount":73},"100621634","evaluation-of-different-sizes-of-left-sided-double-lumen-tubes-for-thoracic-surgery-in-a-tertiary-level-teaching-hospital-100621634","NCT07373171","Evaluation of Different Sizes of Left-Sided Double-Lumen Tubes for Thoracic Surgery in a Tertiary Level Teaching Hospital","Inclusion Criteria:\n\n* Patient aged 18 years or older undergoing thoracic surgery requiring OLV with placement of a left-sided DLT\n\nExclusion Criteria:\n\n* Patient refusal\n* Need for rapid sequence intubation (RSI) due to increased aspiration risk\n* Anticipated difficult intubation\n* Emergency surgery\n* Patient already intubated with a single-lumen ET tube\n* DLT tube change to single lumen tube at the end and shifted with ETT in situ",{"count":193,"type":22},[85],"Double lumen tubes (DLT) have become standard of care for one lung ventilation in thoracic and esophageal surgeries. Selection of accurate size of DLT is important to achieve proper one lung ventilation, prevent trauma to airway, easy intubation, prevention of displacement of DLT and adequate oxygenation intraoperatively. There are no definitive guidelines to select the correct size of DLT. The aim of this study is to observe if there is any difference in the number of intubation attempts, intraoperative oxygenation and postoperative sore throat while using 35 Fr DLT size and other DLT size. The research will be conducted between Ashoj 1st 2082 to Chaitra 30 2082 at Manmohan Cardiothoracic Vascular and Transplant Center(MCVTC). Fifty patients aged more than eighteen years undergoing thoracic surgery requiring One Lung Ventilation(OLV) with left sided DLT will be selected for the study. Participants will be randomly assigned to 35 Fr DLT size group or DLT size group according to the height. Patients in both the groups will be given the samepreoperative care, intraoperative care and postoperative care. Besides patient's demography, diagnosis and operative procedure; number of intubation attempts, modified Cromack-Lehane(CL) grade, size of DLT, intraoperative oxygen saturation SpO₂ and postoperative sore throat on day of surgery and first postoperative day will be recorded. Statistical analysis will be done using t- test for independent variable, confidence interval for outcome of sore throat, significance of difference for number of male and female; rates, risk ratio and odds ratio will be calculated using 2x2 contingency table. P ≤ 0.05 will be considered statistically significant. Our expected outcome is 35 Fr DLT are easier to intubate, does not affect intraoperative oxygenation and decrease the incidence of postoperative sore throat.",[29,624],"Lung Abscess","2026-01-22",{"date":605,"type":39},{"date":628,"type":22},"2026-01",{"date":41,"type":22},{"name":631,"class":101},"Tribhuvan University, Nepal",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":23,"phases":640,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":73},"100619216","phase-1-sl-28-for-advanced-solid-tumours-100619216","NCT07341737","SL-28 for Advanced Solid Tumours","A Phase 1\u002F2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours","Inclusion Criteria:\n\n* Ability to provide written informed consent prior to any study-related procedures and to understand the nature, purpose, and potential risks of the study\n* Adult males and females ≥18 years of age at screening\n* Life expectancy of at least 3 months\n* Histologically or cytologically confirmed unresectable advanced solid tumor (recurrent, metastatic, or locally advanced)\n* Disease refractory to, intolerant of, or refusal of standard therapies, including immunotherapy and molecular\u002Fbiomarker-directed treatments, as determined by the Principal Investigator (PI) or delegate\n* Eligible tumor types include:\n* Head and neck squamous cell carcinoma\n* Thoracic malignancies (small-cell lung cancer, non-small cell lung cancer, esophageal cancer)\n* Gastrointestinal malignancies (gastric, liver, colorectal, pancreatic adenocarcinoma)\n* Genitourinary malignancies (bladder, renal cell, prostate cancer)\n* Gynecologic malignancies (ovarian, endometrial cancer)\n* Breast cancer and melanoma\n* Evaluable disease per RECIST v1.1\n* ECOG performance status 0-1 (or up to 2 at PI discretion)\n* Adequate organ function, defined as:\n* Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for liver metastases or Gilbert's syndrome)\n* AST, ALT, alkaline phosphatase ≤2.5 × ULN (≤5 × ULN if liver metastases, at PI discretion)\n* Creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault) or eGFR ≥50 mL\u002Fmin (CKD-EPI)\n* Absolute neutrophil count ≥1,000\u002Fmm³\n* Platelet count ≥100,000\u002Fmm³\n* Hemoglobin ≥90 g\u002FL without transfusion within 2 weeks\n* Prothrombin time and aPTT ≤1.5 × ULN (or stable INR if on anticoagulation)\n\nFemale patients:\n\n-Non-childbearing potential (surgically sterile or postmenopausal), or of childbearing potential with negative pregnancy tests and agreement to effective contraception through 90 days post-dose\n\nMale patients:\n\n* Agreement not to donate sperm for 90 days post-dose\n* Agreement to use adequate contraception as applicable\n* Suitable venous access for blood sampling\n* Willingness and ability to comply with study procedures and protocol requirements\n\nExclusion Criteria:\n\n* Ongoing toxicities ≥ Grade 2 per NCI CTCAE v5.0 (except alopecia, fatigue, sensory neuropathy, or adequately treated endocrine deficiencies)\n* NYHA Class III or IV heart disease, myocardial infarction within 6 months, unstable arrhythmia, or ischemia on ECG\n* QTcF \\>470 ms (females) or \\>450 ms (males)\n* Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy\n* Requirement for systemic corticosteroids or other immunosuppressive therapy that cannot be discontinued ≥14 days prior to dosing\n* Prior therapies within restricted timeframes:\n* Immune checkpoint inhibitors or biologics within 28 days\n* Antineoplastic therapies, surgery, radiotherapy, or radiopharmaceuticals within 21 days\n* Unapproved investigational drugs within 5 half-lives\n* Nitrosoureas or mitomycin C within 6 weeks\n* Concurrent malignancy within 5 years, except specified low-risk cancers\n* Pregnancy or breastfeeding\n* Known HIV, hepatitis B (HBsAg positive), or hepatitis C infection\n* Inability or unwillingness to comply with protocol procedures\n* History of anaphylaxis or significant allergy interfering with participation\n* Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, neurologic, psychiatric, or immunologic disease within 6 months\n* Conditions affecting drug absorption, distribution, metabolism, or excretion\n* Receipt of live vaccines within 28 days prior to screening\n* Participation in another investigational study within 30 days prior to screening",{"count":193,"type":22},[25,112],"Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.",[643,644,645,29,466,646,647,648,649,650,651,652,653,654,416,168,169,655],"Head & Neck Cancer","Pancreas Carcinoma","Pancreas Cancer, Metastatic","Lung Cancer (Non-Small Cell)","Esophageal Cancer","Stomach (Gastric) Cancer","Liver Cancer","Intestinal Cancer","Bladder Cancer","Renal Cancer","Prostate Cancer","Melanoma (Skin Cancer)","Colorectal Cancer","2026-01-13",{"date":658,"type":39},"2026-01-15",{"date":660,"type":22},"2026-02-01",{"date":662,"type":22},"2027-03-01",{"name":664,"class":46},"Second Life Therapeutics",{"id":666,"slug":667,"hasResults":12,"nctId":668,"briefTitle":669,"officialTitle":670,"acronym":671,"eligibilityCriteria":672,"healthyVolunteers":245,"sex":18,"minAge":19,"maxAge":673,"enrollmentInfo":674,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":676,"conditions":677,"keywords":680,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":687,"completionDateStruct":688,"leadSponsor":689,"locationsCount":4},"100613952","adh1b-and-aldh-gene-variants-and-lung-cancer-risk-100613952","NCT07273279","ADH1B and ALDH Gene Variants and Lung Cancer Risk","Associations of ADH1B and ALDH Family Gene Polymorphisms With Lung Cancer Risk and Its Subtypes: Results From the Oncoarray Project of the International Lung Cancer Consortium","ALDH","Inclusion Criteria:\n\n* Incident lung cancer cases confirmed by pathology and healthy adult over age of 18 years.\n\nExclusion Criteria:\n\n* Individuals with incomplete data will not be included as study participants.","99 Years",{"count":675,"type":22},100000,"Lung cancer in never-smokers is increasingly recognized as a disease influenced by genetic susceptibility. Aldehyde-metabolizing enzymes, including the ALDH gene family and ADH1B, play key roles in detoxifying reactive aldehydes that can damage DNA and promote oxidative stress. In this study, we will examine whether ten selected genetic variants, nine single nucleotide polymorphisms (SNPs) across five ALDH family genes and one variant in ADH1B are associated with the risk of lung cancer and its major subtypes. Limited epidemiological evidence is currently available on the association between these aldehyde-metabolizing gene variants and lung cancer. This research aims to clarify their potential contribution to the development of lung cancer, particularly among never-smokers.",[678,679,29],"Condition\u002FDisease","Lung Cancer (Diagnosis)",[681,682,683],"ALDH2","ADH1B","Lung cancer","2025-11-26",{"date":686,"type":39},"2025-12-09",{"date":628,"type":22},{"date":283,"type":22},{"name":690,"class":101},"Kaohsiung Medical University"]